Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
奥希替尼联合或不联合沙沃替尼作为MET异常、EGFR突变型非小细胞肺癌的一线治疗：随机2期试验（FLOWERS）
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-67950-8
Li, Anna; Feng, Wei-Neng; Li, Juan; Xu, Bing-Fei; Zhao, Jun; Jia, Yun; Tang, Ke-Jing; Li, Yong-Sheng; Zhou, Cheng-Zhi; Fan, Yun; Xu, Chong-Rui; Sun, Yue-Li; Chen, Hua-Jun; Yan, Hong-Hong; Shi, Zong-Kun; Yang, Jin-Ji
